Deciphera LogoBREAKING NEWS!

Published today in Targeted Oncology

A New Drug Application (NDA) for ripretinib (DCC-2618) was submitted to the FDA for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received a prior treatment of imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), according to a press release from Deciphera Pharmaceuticals, Inc.

Read more…